Clinical Trial Update: Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of ibrexafungerp in healthy lactating women completed; results were posted on 2025-08-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis
• Vulvovaginal Candidiasis

Drugs mentioned

• Brexafemme (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Vulvovaginal Candidiasis, Candida Infection | Phase 1 | Status: COMPLETED | Results posted: 2025-08-08